

Supplementary Table 1. ORR and response

Response	No. of Patients (%)			<i>P</i>
	Total	B+PP (n=22)	PP (n=37)	
CR	0 (0)	0 (0)	0 (0)	
PR	32 (54.2)	11 (50.0)	21 (56.8)	
SD	23 (39.0)	9 (40.9)	14 (37.8)	
PD	4 (6.8)	2 (9.1)	2 (5.4)	
ORR	32 (54.2)	11 (50.0)	21 (56.8)	0.614
DCR	55 (93.2)	20 (90.9)	35 (94.6)	0.093

Abbreviations: B+PP, bevacizumab plus pemetrexed-platinum; PP, pemetrexed-platinum; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate; DCR, disease control rate.

Supplementary Table 2. Adverse events

Adverse Events	No. of Patients (%)			<i>P</i>
	Total	B+PP (n=22)	PP (n=37)	
Any grade	44 (74.6)	15 (68.2)	29 (78.4)	0.384
Hematologic	28 (47.5)	11 (50.0)	17 (45.9)	
Gastrointestinal	32 (54.2)	11 (50.0)	21 (56.8)	
Hypertension	3 (5.1)	3 (13.6)	0 (0)	
Thrombosis	0 (0)	0 (0)	0 (0)	
Hemorrhage	0 (0)	0 (0)	0 (0)	
Pneumonia	0 (0)	0 (0)	0 (0)	
Grade ≥3	10 (16.9)	6 (27.3)	4 (10.8)	0.204
Hematologic	7 (11.9)	5 (22.7)	2 (5.4)	
Gastrointestinal	3 (5.1)	1 (4.5)	2 (5.4)	
Hypertension	1 (1.7)	1 (4.5)	0 (0)	
AE leading to death	0 (0)	0 (0)	0 (0)	
AE leading to drug withdrawal	2 (3.4)	2 (9.1)	0 (0)	